Dexcom, Inc. Files 8-K on Security Holder Vote Matters

Ticker: DXCM · Form: 8-K · Filed: 2024-05-24T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: DXCM

TL;DR

DXCM filed an 8-K about a shareholder vote - details to follow.

AI Summary

On May 22, 2024, Dexcom, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not disclose specific proposals or outcomes of any votes, but indicates that a shareholder meeting or vote is scheduled or has occurred.

Why It Matters

This filing signals that Dexcom is engaging in corporate governance processes, which may involve significant decisions affecting shareholders.

Risk Assessment

Risk Level: low — The filing is procedural and does not contain information about financial performance or significant operational changes.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Dexcom, Inc.'s security holders?

The filing does not specify the exact matters submitted for a vote, only that such matters were presented.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on May 22, 2024.

What is Dexcom, Inc.'s state of incorporation?

Dexcom, Inc. is incorporated in Delaware.

What is the principal executive office address for Dexcom, Inc.?

The principal executive offices are located at 6340 Sequence Drive, San Diego, CA 92121.

What is the purpose of this Form 8-K filing for Dexcom, Inc.?

The purpose of the filing is to report the submission of matters to a vote of security holders.

From the Filing

0001093557-24-000101.txt : 20240524 0001093557-24-000101.hdr.sgml : 20240524 20240524161245 ACCESSION NUMBER: 0001093557-24-000101 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240522 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240524 DATE AS OF CHANGE: 20240524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 24984469 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 dxcm-20240522.htm 8-K dxcm-20240522 false 0001093557 0001093557 2024-05-22 2024-05-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 22, 2024 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive , San Diego , CA 92121 (Address of Principal Executive Offices) ( Zip Code) ( 858 ) 200-0200 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. On May 22, 2024, DexCom, Inc. (“Dexcom” or the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the close of business on March 27, 2024, the record date for the Annual Meeting, there were 396,025,556 shares of Dexcom’s common stock, $0.001 par value per share, outstanding and entitled to vote. 362,430,100 shares were present in person or represented by proxy at the Annual Meeting, which constituted a quorum for the transaction of business. The matters described below were voted on at the Annual Meeting and the final number of votes cast for or against, as well as the number of abstentions and broker non-votes, with respect to each matter are as indicated. Proposal 1: Election of Directors . Dexcom stockholders elected the following ten nominees to the Company’s board of directors, each to serve u

View on Read The Filing